Microglia, for example, have been identified as molecular drivers in AD pathogenesis, whereby changes in the concentrations of microglial markers (such as Ionized calcium‐binding adaptor molecule 1 (Iba1), Transmembrane protein 119 (TMEM119), and Purinergic receptor P2Y12 (P2RY12) have been observed in patients with AD.24 This evidence concerns the gene TMEM119 and Alzheimer disease.